Andrew Reardon sold $1.4M of LGND
CLO & Secretary at LIGAND PHARMACEUTICALS INC. 5,000 shares at an average of $288.99, traded Aug 3, 2026, filed Aug 4, 2026.
Score components
- +15RoleOfficer
- +25Trade size$1.4M at market
- +5Share of holdings soldSold 11% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0002001011-26-000111, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 3, 2026 | MOption exercise Common Stock10b5-1 | +5,000 | $52.27 | $261k | 46,514 | Aug 4, 2026 |
| Aug 3, 2026 | SOpen-market sale Common Stock10b5-1 | -105 | $284.14 | $30k | 46,409 | Aug 4, 2026 |
| Aug 3, 2026 | SOpen-market sale Common Stock10b5-1 | -33 | $284.55 | $9,390 | 46,376 | Aug 4, 2026 |
| Aug 3, 2026 | SOpen-market sale Common Stock10b5-1 | -157 | $285.74 | $45k | 46,219 | Aug 4, 2026 |
| Aug 3, 2026 | SOpen-market sale Common Stock10b5-1 | -1,032 | $286.80 | $296k | 45,187 | Aug 4, 2026 |
| Aug 3, 2026 | SOpen-market sale Common Stock10b5-1 | -1,214 | $287.77 | $349k | 43,973 | Aug 4, 2026 |
| Aug 3, 2026 | SOpen-market sale Common Stock10b5-1 | -356 | $288.75 | $103k | 43,617 | Aug 4, 2026 |
| Aug 3, 2026 | SOpen-market sale Common Stock10b5-1 | -503 | $289.80 | $146k | 43,114 | Aug 4, 2026 |
| Aug 3, 2026 | SOpen-market sale Common Stock10b5-1 | -200 | $290.60 | $58k | 42,914 | Aug 4, 2026 |
| Aug 3, 2026 | SOpen-market sale Common Stock10b5-1 | -991 | $291.71 | $289k | 41,923 | Aug 4, 2026 |
| Aug 3, 2026 | SOpen-market sale Common Stock10b5-1 | -409 | $292.82 | $120k | 41,514 | Aug 4, 2026 |
| Aug 3, 2026 | MOption exercise Employee Stock Option (right to buy)derivative10b5-1 | -5,000 | $0.00 | $0 | 29,444 | Aug 4, 2026 |
Related signals
Other insiders at LIGAND PHARMACEUTICALS INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 10Weak | LIGAND PHARMACEUTICALS INC | Andrew Reardon CLO & Secretary | $1.5M 5,000 shares | -14% | |
| 43Moderate | LIGAND PHARMACEUTICALS INC | Martine Zimmermann director | $342k 1,200 shares | -24% | |
| 33Weak | LIGAND PHARMACEUTICALS INC | Andrew Reardon CLO & Secretary | $1.4M 5,000 shares | -12% | |
| 47Moderate | LIGAND PHARMACEUTICALS INC | Octavio Espinoza Chief Financial Officer | $9.2M 31,641 shares | -53% | |
| 60Notable | LIGAND PHARMACEUTICALS INC | Jason Haas director | $2.1M 7,138 shares | -64% | |
| 10Weak | LIGAND PHARMACEUTICALS INC | Andrew Reardon CLO & Secretary | $1.6M 5,000 shares | -11% | |
| 34Weak | LIGAND PHARMACEUTICALS INC | Stephen L Sabba director | $545k 2,145 shares | -6% | |
| 60Notable | LIGAND PHARMACEUTICALS INC | Jason Haas director | $1.7M 6,461 shares | -56% | |
| 55Moderate | LIGAND PHARMACEUTICALS INC | Jason Aryeh director | $1.3M 5,000 shares | -5% | |
| 60Notable | LIGAND PHARMACEUTICALS INC | John L Lamattina director | $1.2M 4,591 shares | -15% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.